公开(公告)号：US20180355063A1

公开(公告)日：2018-12-13

申请号：US15779428

申请日：2016-12-01

Applicant: UCB BIOPHARMA SPRL

Inventor： Helene Margaret FINNEY

IPC: C07K16/46 ,  C07K16/14 ,  C07K14/39 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/468 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/575 ,  A61P35/00 ,  C07K14/39 ,  C07K16/00 ,  C07K16/14 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/035 ,  C07K2319/30 ,  C07K2319/33

Abstract: The present invention is directed to a method of controlling and directing cells, for example to stimulate an immune response, inhibit an immune response, direct tissue regeneration or prevent tissue damage for therapeutic activity through the use of heterodimerically-tethered bispecific protein complex of formula A-X:Y-B. Component A may present X on the surface of a cell, may bind a protein (including a marker) expressed on the surface of an effector cell, or A-X is expressed on the surface of an effector cell, whilst B is specific to an epitope on target cell or tissue of interest. X:Y is a heterodimeric-tether which is formed by a binding interaction between X and Y, which together with A and B assists and effects the controlling and directing of the selected cells.

公开(公告)号：US20180337485A1

公开(公告)日：2018-11-22

申请号：US15777483

申请日：2016-11-17

Applicant: UCB Biopharma SPRL

Inventor： Barry Alan KNIGHT ,  Oliver Frederik STUMPP

IPC: H01R13/516 ,  H01R13/62

CPC classification number: H01R13/516 ,  H01R13/62

Abstract: Provided is a housing for a USB connector plug comprising a body for partly surrounding the USB connector plug, the body defining a forward aperture from which a plug head of the USB connector plug extends and a rearward aperture from which a cable of the USB connector plug extends. The body has an outer form, which defines on a first surface thereof, a thumb pad and on a second opposing surface, a finger pad. The outer form of the body is provided with a thumb push element that stands proud from a forward part of the thumb pad. The housing may also be configured as an over-housing for a conventional USB connector plug.

公开(公告)号：US10105359B2

公开(公告)日：2018-10-23

申请号：US15517795

申请日：2015-10-06

Applicant: UCB Biopharma SPRL

Inventor： Anne Valade ,  Eric Jnoff ,  Ali Ates ,  Pierre Burssens ,  David Skolc ,  Zara Sands ,  Benoit Mathieu

IPC: C07D217/06 ,  A61K31/4725 ,  C07D401/06 ,  C07D403/06 ,  C07D413/04

Abstract: The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.

公开(公告)号：US10087180B2

公开(公告)日：2018-10-02

申请号：US15318473

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Daniel James Ford ,  James Thomas Reuberson

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/496

Abstract: A series of pyrazolo[3,4-b]pyridine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US10053464B2

公开(公告)日：2018-08-21

申请号：US15039073

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Daniel Christopher Brookings

IPC: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377

Abstract: A series of substituted [1,2,4]triazolo[4,3-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20180172702A1

公开(公告)日：2018-06-21

申请号：US15736520

申请日：2015-10-22

Applicant: UCB Biopharma SPRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  Graham John WARRELLOW

IPC: G01N33/68

Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

公开(公告)号：US10000497B2

公开(公告)日：2018-06-19

申请号：US15318507

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Helen Tracey Horsley ,  Qiuya Huang ,  Judi Charlotte Neuss ,  James Thomas Reuberson ,  Bart Vanderhoydonck

IPC: C07D487/04 ,  C07D403/04 ,  A61K31/53 ,  A61K31/495 ,  A61P33/06 ,  A61P37/06

CPC classification number: C07D487/04 ,  A61K31/495 ,  A61K31/53 ,  C07D403/04 ,  Y02A50/411

Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US09969728B2

公开(公告)日：2018-05-15

申请号：US15038239

申请日：2014-12-08

Applicant: UCB Biopharma SPRL

Inventor： Sabine Defays ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  James Andrew Johnson ,  Boris Kroeplien ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4184

CPC classification number: C07D471/04 ,  A61K31/4184 ,  A61K31/437 ,  A61K2300/00

Abstract: A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09957255B2

公开(公告)日：2018-05-01

申请号：US15101073

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Daniel Christopher Brookings ,  Boris Kroeplien

IPC: C07D403/04 ,  C07D413/14 ,  C07D413/04 ,  C07D249/18 ,  A61K31/506 ,  A61K31/5377

CPC classification number: C07D403/04 ,  A61K31/506 ,  A61K31/5377 ,  C07D249/18 ,  C07D413/04 ,  C07D413/14

Abstract: A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US09926313B2

公开(公告)日：2018-03-27

申请号：US15101089

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/506

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506

Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.